TrialJournal of diabetes investigation2022

Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.

Daisuke Yabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.